GlassScriptPhysician profile
Andrew S Nicholson
NPI 1295912665
$2,805.72
in general payments reported to CMS, 2019-2025
20 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $169 · 2021: $425 · 2022: $556 · 2023: $576 · 2024: $377 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.06 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $647.71 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $489.26 | 2021-2023 | Veozah |
| Glaxosmithkline, LLC. | $320.14 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.09 | 2019-2023 | Tradjenta |
| Abbvie INC. | $190.86 | 2022-2023 | |
| Lilly USA, LLC | $157.70 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $153.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $104.85 | 2021-2023 | Verquvo, Belsomra |
| Sunovion Pharmaceuticals INC. | $103.05 | 2021-2022 | |
| Corcept Therapeutics | $70.70 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $65.12 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $61.00 | 2021-2022 | |
| Dexcom, INC. | $52.78 | 2023-2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $27.30 | 2024 | |
| Verona Pharma, INC. | $25.74 | 2025 | Ohtuvayre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $25.65 | 2025 | Brixadi |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Esperion Therapeutics, INC. | $18.48 | 2020 | |
| Indivior INC. | $15.28 | 2023 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.